CSPC Pharma Secures NMPA Approval to Launch Clinical Trials for First Recombinant Herpes Zoster Vaccine

Bulletin Express

Jul 02

CSPC Pharmaceutical Group Limited (CSPC Pharma) has received clearance from China’s National Medical Products Administration to initiate clinical trials for its recombinant herpes zoster vaccine, SYS6052.

The vaccine candidate combines varicella-zoster virus glycoprotein E (gE) with a proprietary nanoadjuvant system developed in-house. Pre-clinical studies indicated favorable safety and efficacy profiles, with the optimized antigen–adjuvant pairing designed to elicit robust humoral and cellular immune responses.

SYS6052 targets the prevention of herpes zoster and related complications in adults aged 50 years and above. This marks CSPC Pharma’s first recombinant protein vaccine to reach the clinical-trial stage, representing a significant milestone in the group’s strategic expansion into preventive vaccines.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1168230838"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1168230838\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1168230838?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-02 19:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168230838","market":"us","top_or_hot":-1,"title":"CSPC Pharma Secures NMPA Approval to Launch Clinical Trials for First Recombinant Herpes Zoster Vaccine","media":"Bulletin Express","content":"<p>CSPC Pharmaceutical Group Limited (CSPC Pharma) has received clearance from China’s National Medical Products Administration to initiate clinical trials for its recombinant herpes zoster vaccine, SYS6052.</p>\n<p>The vaccine candidate combines varicella-zoster virus glycoprotein E (gE) with a proprietary nanoadjuvant system developed in-house. Pre-clinical studies indicated favorable safety and efficacy profiles, with the optimized antigen–adjuvant pairing designed to elicit robust humoral and cellular immune responses.</p>\n<p>SYS6052 targets the prevention of herpes zoster and related complications in adults aged 50 years and above. This marks CSPC Pharma’s first recombinant protein vaccine to reach the clinical-trial stage, representing a significant milestone in the group’s strategic expansion into preventive vaccines.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSPC Pharma Secures NMPA Approval to Launch Clinical Trials for First Recombinant Herpes Zoster Vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSPC Pharma Secures NMPA Approval to Launch Clinical Trials for First Recombinant Herpes Zoster Vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-02 19:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CSPC Pharmaceutical Group Limited (CSPC Pharma) has received clearance from China’s National Medical Products Administration to initiate clinical trials for its recombinant herpes zoster vaccine, SYS6052.</p>\n<p>The vaccine candidate combines varicella-zoster virus glycoprotein E (gE) with a proprietary nanoadjuvant system developed in-house. Pre-clinical studies indicated favorable safety and efficacy profiles, with the optimized antigen–adjuvant pairing designed to elicit robust humoral and cellular immune responses.</p>\n<p>SYS6052 targets the prevention of herpes zoster and related complications in adults aged 50 years and above. This marks CSPC Pharma’s first recombinant protein vaccine to reach the clinical-trial stage, representing a significant milestone in the group’s strategic expansion into preventive vaccines.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01093","symbol_name":"石药集团","start_time":0,"source_url":"","article_id":"1168230838","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168230838","pubTimestamp":1782990439,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CSPC Pharmaceutical Group Limited (CSPC Pharma) has received clearance from China’s National Medical Products Administration to initiate clinical trials for its recombinant herpes zoster vaccine,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01093":"石药集团"},"translate_title":"石药集团首个重组带状疱疹疫苗获NMPA批准启动临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"CSPC Pharmaceutical Group Limited (CSPC Pharma) has received clearance from China’s National Medical Products Administration to initiate clinical trials for its recombinant herpes zoster vaccine, SYS6052.\nThe vaccine candidate combines varicella-zoster virus glycoprotein E (gE) with a proprietary nanoadjuvant system developed in-house. Pre-clinical studies indicated favorable safety and efficacy profiles, with the optimized antigen–adjuvant pairing designed to elicit robust humoral and cellular immune responses.\nSYS6052 targets the prevention of herpes zoster and related complications in adults aged 50 years and above. This marks CSPC Pharma’s first recombinant protein vaccine to reach the clinical-trial stage, representing a significant milestone in the group’s strategic expansion into preventive vaccines.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}